Pediatrix Medical Group, Inc. (MD) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
20.98$'dan işlem gören Pediatrix Medical Group, Inc. (MD), $1.80B değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 49/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 9 Şub 2026Pediatrix Medical Group, Inc. (MD) Sağlık ve Boru Hattı Genel Bakışı
Pediatrix Medical Group offers specialized care for newborns, mothers, and children, leveraging a comprehensive network of physicians and a focus on high-growth pediatric subspecialties. With a P/E of 11.00 and a solid 8.4% profit margin, MD presents a compelling value proposition in the healthcare sector.
Yatırım Tezi
Pediatrix Medical Group presents a notable research candidate due to its specialized focus and established market presence. With a P/E ratio of 11.00 and a profit margin of 8.4%, the company demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pediatric and maternal care, driven by advancements in medical technology and a growing awareness of complex health issues in newborns and children. Growth catalysts include expanding service offerings within existing markets and strategic acquisitions to broaden geographic reach. The company's beta of 0.78 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. Continued focus on operational efficiency and strategic partnerships should further enhance profitability and shareholder value.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $1.79 billion, reflecting substantial investor confidence in the company's market position.
- P/E ratio of 11.00, indicating a potentially undervalued stock compared to its earnings.
- Profit margin of 8.4%, demonstrating efficient operations and profitability in the healthcare services sector.
- Gross margin of 25.8%, showcasing the company's ability to manage costs effectively.
- Beta of 0.78, suggesting lower volatility compared to the broader market, appealing to risk-averse investors.
Rakipler & Benzerleri
Güçlü Yönler
- Specialized expertise in high-demand pediatric and maternal care services.
- Extensive network of physicians and hospital partnerships.
- Strong reputation for quality care and positive patient outcomes.
- Established market presence and brand recognition.
Zayıflıklar
- Dependence on reimbursement rates and regulatory policies.
- Potential for physician turnover and staffing challenges.
- Geographic concentration in certain markets.
- Exposure to medical malpractice claims and litigation.
Katalizörler
- Upcoming: Expansion of telehealth services to improve access to care and increase revenue.
- Ongoing: Strategic acquisitions of smaller practices to broaden geographic presence and service offerings.
- Ongoing: Development and launch of specialized pediatric programs to attract more patients.
- Ongoing: Enhancement of maternal-fetal medicine services to address growing demand for prenatal care.
Riskler
- Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.
- Potential: Increased competition from other healthcare providers could erode market share.
- Potential: Economic downturns could affect patient volumes and healthcare spending.
- Ongoing: Medical malpractice claims and litigation could result in significant financial losses.
- Ongoing: Physician turnover and staffing challenges could disrupt operations and impact quality of care.
Büyüme Fırsatları
- Expansion of Telehealth Services: Pediatrix can leverage telehealth to extend its reach to underserved areas and improve access to specialized care. The telehealth market is projected to reach $400 billion by 2028, offering a significant growth opportunity. By investing in telehealth infrastructure and virtual care programs, Pediatrix can enhance patient engagement and improve outcomes, driving revenue growth and market share.
- Strategic Acquisitions and Partnerships: Pediatrix can pursue strategic acquisitions of smaller pediatric practices and partnerships with hospitals to expand its network and service offerings. This approach allows the company to enter new markets quickly and efficiently, leveraging existing infrastructure and expertise. Targeted acquisitions in high-growth areas can significantly boost revenue and profitability within the next 3-5 years.
- Development of Specialized Pediatric Programs: Focusing on developing specialized programs for specific pediatric conditions, such as pediatric cardiology and neurology, can attract more patients and increase revenue. These programs can be marketed to hospitals and healthcare systems, creating a recurring revenue stream. The market for specialized pediatric care is growing, driven by advancements in medical technology and increasing awareness of complex health issues.
- Enhancement of Maternal-Fetal Medicine Services: Expanding maternal-fetal medicine services to address the growing demand for prenatal care and high-risk pregnancy management can drive significant growth. This includes offering advanced diagnostic testing, genetic counseling, and specialized care for expectant mothers with complex medical conditions. The maternal-fetal medicine market is expected to grow at a CAGR of 6% over the next five years, presenting a substantial opportunity for Pediatrix.
- Investment in Data Analytics and AI: Utilizing data analytics and artificial intelligence to improve clinical outcomes, optimize operations, and personalize patient care can provide a competitive advantage. By analyzing patient data, Pediatrix can identify trends, predict potential health issues, and develop targeted interventions. This can lead to improved patient satisfaction, reduced costs, and increased efficiency, driving long-term growth and profitability.
Fırsatlar
- Expansion of telehealth services to reach underserved areas.
- Strategic acquisitions and partnerships to broaden geographic reach.
- Development of specialized pediatric programs for specific conditions.
- Enhancement of maternal-fetal medicine services to address growing demand.
Tehditler
- Changes in healthcare regulations and reimbursement policies.
- Increased competition from other healthcare providers.
- Economic downturns affecting patient volumes and healthcare spending.
- Potential for medical malpractice claims and litigation.
Rekabet Avantajları
- Specialized Expertise: Deep expertise in neonatal, maternal-fetal, and pediatric cardiology care creates a barrier to entry.
- Extensive Network: A large network of physicians and hospital partnerships provides a competitive advantage.
- Reputation: A strong reputation for quality care and positive patient outcomes enhances brand loyalty.
- Scale: The company's size and scale allow for economies of scale and efficient operations.
MD Hakkında
Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix Medical Group, Inc. has evolved into a leading provider of specialized medical care. Originally known as MEDNAX, Inc., the company rebranded in July 2022 to better reflect its core focus on pediatric and maternal health. Pediatrix operates across the United States and Puerto Rico, offering a comprehensive suite of services including neonatal care, maternal-fetal care, pediatric cardiology, and other pediatric subspecialty services. Their neonatal care focuses on premature babies and those with complications, providing clinical care within hospital units. Maternal-fetal care includes inpatient and office-based services for expectant mothers and unborn babies. Pediatric cardiology addresses congenital heart defects and acquired heart disease. The company also offers specialized services in pediatric intensive care, hospitalist care, surgery, ophthalmology, and ENT. As of February 17, 2022, Pediatrix operated a network of approximately 2,700 physicians, solidifying its position as a key player in specialized pediatric and maternal healthcare.
Ne Yaparlar
- Provides clinical care to premature babies and newborns with complications.
- Offers inpatient and office-based care to expectant mothers and unborn babies.
- Delivers pediatric cardiology care for congenital heart defects and acquired heart disease.
- Provides specialized cardiac care to fetuses, neonates, and pediatric patients.
- Offers pediatric subspecialty care through intensivists, hospitalists, surgeons, and ophthalmologists.
- Supports hospitals in pediatric emergency rooms, labor and delivery areas, and nursery departments.
- Operates a network of approximately 2,700 physicians across the United States and Puerto Rico.
İş Modeli
- Generates revenue through providing specialized medical care services.
- Contracts with hospitals and healthcare systems to provide physician staffing and management.
- Receives payments from insurance companies, government programs, and patients for services rendered.
- Expands service offerings and geographic reach through strategic acquisitions and partnerships.
Sektör Bağlamı
Pediatrix Medical Group operates within the medical care facilities industry, which is experiencing steady growth driven by increasing demand for specialized healthcare services. The market is characterized by a mix of large national providers and smaller regional players. Key trends include the growing prevalence of chronic conditions in children and the increasing need for specialized neonatal and maternal-fetal care. The competitive landscape includes companies like Acadia Healthcare (ACHC) and American Addiction Centers (ADUS), which focus on behavioral health, while Pediatrix specializes in pediatric and maternal care. The industry is also influenced by regulatory changes and reimbursement policies, requiring companies to adapt to evolving healthcare standards.
Kilit Müşteriler
- Hospitals and healthcare systems seeking specialized pediatric and maternal care services.
- Expectant mothers requiring maternal-fetal medicine services.
- Newborns and children needing neonatal and pediatric subspecialty care.
- Insurance companies and government programs covering healthcare costs.
Finansallar
Grafik & Bilgi
Pediatrix Medical Group, Inc. (MD) hisse senedi fiyatı: $20.98 (-0.21, -0.99%)
Son Haberler
-
Pediatrix Medical Partners With Tennessee Maternal-Fetal Medicine
MT Newswires · 26 Mar 2026
-
Pediatrix Medical Group Expands Tennessee Footprint Through Collaboration With Tennessee Maternal-Fetal Medicine
benzinga · 26 Mar 2026
-
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
businesswire.com · 26 Mar 2026
-
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
businesswire.com · 24 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MD için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $20.67
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MD'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
Pediatrix Medical Partners With Tennessee Maternal-Fetal Medicine
Pediatrix Medical Group Expands Tennessee Footprint Through Collaboration With Tennessee Maternal-Fetal Medicine
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
Pediatrix Medical Group, Inc. Hissesi: Cevaplanan Temel Sorular
MD için değerlendirilmesi gereken temel faktörler nelerdir?
Pediatrix Medical Group, Inc. (MD) şu anda yapay zeka skoru 49/100, düşük puanı gösteriyor. Hisse 10.7x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) altında, potansiyel değer sinyali. Analist hedefi $20.67 ($20.98'dan -1%). Temel güçlü yan: Specialized expertise in high-demand pediatric and maternal care services.. İzlenmesi gereken birincil risk: Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.. Bu bir finansal tavsiye değildir.
MD MoonshotScore'u nedir?
MD şu anda MoonshotScore'da 49/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MD verileri ne sıklıkla güncellenir?
MD fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MD hakkında ne diyor?
Analistler, MD için $20.67 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($20.98) aşağı yönlü %1 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
MD'a yatırım yapmanın riskleri nelerdir?
MD için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MD'ın P/E oranı nedir?
Pediatrix Medical Group, Inc. (MD)'nın son P/E oranı 10.7, ki bu da piyasa ortalamasının altında, bu da göreli değeri gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
MD aşırı değerli mi, yoksa düşük değerli mi?
Pediatrix Medical Group, Inc. (MD)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 10.7. Analist hedefi $20.67 (mevcut fiyattan -1%), analistlerin hisse senedini adil değere yakın gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MD'ın temettü verimi nedir?
Pediatrix Medical Group, Inc. (MD) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Stock data pending update.
- Information is based on available data as of February 9, 2026.